CSS LLC’s CRISPR Therapeutics CRSP Stock Holding History

CSS LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,900	Closed	-$750K	–	955
2020 Q4	$750K	Buy	+4,900	New	+$579K	0.03%	384

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CSS LLC's CRSP Position: Q1 2021 in Review

CSS LLC sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 1,000 shares — an estimated $153K sold.

CSS LLC first reported a position in CRSP in Q4 2020 and held it in 1 quarter. The position peaked at $153K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

CSS LLC reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
CSS LLC sold 1,000 CRISPR Therapeutics shares in Q1 2021, an estimated $153K.
CSS LLC first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 1 quarter.
CSS LLC's CRISPR Therapeutics position peaked at $153K in Q4 2020.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on CSS LLC's 13F filing for Q1 2021, filed 17 May 2021.